GlassScriptPhysician profile
April D Thompson
NPI 1881281780
$3,066.73
in general payments reported to CMS, 2019-2025
31 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $307 · 2022: $315 · 2023: $524 · 2024: $791 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,444.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $963.76 | 2021-2025 | |
| Pfizer INC. | $298.35 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $245.91 | 2021-2025 | Entyvio, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.75 | 2022-2025 | Xifaxan, Trulance |
| Gilead Sciences, INC. | $180.87 | 2024-2025 | Livdelzi |
| Phathom Pharmaceuticals, INC. | $145.74 | 2024-2025 | Voquezna |
| Aimmune Therapeutics, INC. | $144.86 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $95.35 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $82.93 | 2023-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $82.72 | 2022-2024 | Dificid |
| Genzyme Corporation | $65.88 | 2025 | |
| Neuraxis, INC. | $57.73 | 2025 | |
| Madrigal Pharmaceuticals | $50.56 | 2025 | Rezdiffra |
| Celltrion USA INC. | $47.79 | 2024-2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $38.62 | 2023-2024 | Dupixent |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $36.49 | 2022-2024 | Zeposia |
| Medtronic, INC. | $35.70 | 2024 | Interstim |
| Daiichi Sankyo INC. | $27.38 | 2023 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $26.52 | 2024 | Iqirvo |
| Boston Scientific Corporation | $24.88 | 2024 | Watchman Flx |
| Axonics, INC. | $24.55 | 2024 | Axonics |
| Lucid Diagnostics INC. | $21.65 | 2023 | |
| Ferring Pharmaceuticals INC. | $20.00 | 2025 | Rebyota |
| Palette Life Sciences, INC. | $19.83 | 2023 | |
| Braintree Laboratories, INC. | $18.40 | 2023 | Sutab |
| Redhill Biopharma INC. | $17.38 | 2022 | |
| Celgene Corporation | $16.67 | 2022 | |
| Janssen Biotech, INC. | $15.00 | 2025 | Tremfya |
| Fresenius Kabi USA, LLC | $14.81 | 2024 | Idacio |
| Nestle Healthcare Nutrition INC. | $14.70 | 2023 | |
| Shield Therapeutics INC | $13.95 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw April Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.